--- title: "Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results" description: "Cellectis (NASDAQ:CLLS) reported its quarterly earnings, posting a loss of ($0.18) per share. The biotechnology company has a negative net margin of 234.39% and a negative return on equity of 74.55%. " type: "news" locale: "en" url: "https://longbridge.com/en/news/240257085.md" published_at: "2025-05-15T00:30:10.000Z" --- # Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results > Cellectis (NASDAQ:CLLS) reported its quarterly earnings, posting a loss of ($0.18) per share. The biotechnology company has a negative net margin of 234.39% and a negative return on equity of 74.55%. Shares traded down 4.4% to $1.51, with a market cap of $83.93 million. Analyst ratings have upgraded Cellectis from "hold" to "buy". The company focuses on developing immuno-oncology products targeting cancer cells. Cellectis (NASDAQ:CLLS - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, Zacks reports. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. ## Cellectis Trading Down 4.4% - Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal Shares of NASDAQ CLLS traded down $0.07 during trading on Monday, hitting $1.51. 24,659 shares of the company were exchanged, compared to its average volume of 142,061. The company has a fifty day moving average price of $1.36 and a 200-day moving average price of $1.59. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The firm has a market capitalization of $83.93 million, a PE ratio of -1.16 and a beta of 3.11. Cellectis has a 12-month low of $1.10 and a 12-month high of $3.10. ## Analyst Ratings Changes Separately, StockNews.com upgraded Cellectis from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. **Read Our Latest Analysis on Cellectis** ## Cellectis Company Profile (Get Free Report) Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. ## Further Reading - Five stocks we like better than Cellectis - How to Calculate Stock Profit - Palantir’s Latest Deal Could Put a Freeze on Its Stock Price - CD Calculator: Certificate of Deposit Calculator - 4 Automaker Stocks React to Tariffs: Winners and Losers - Pros And Cons Of Monthly Dividend Stocks - Here's Why Call Option Traders Love Dutch Bros Stock *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Cellectis Right Now? Before you consider Cellectis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list. While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CLLS.US - Cellectis](https://longbridge.com/en/quote/CLLS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Cellectis SA 報告稱，截至 2025 年 12 月，公司擁有 1.003 億股和 1.056 億投票權 | Cellectis SA 報告稱，截至 2025 年 12 月 31 日，其已發行股份為 100,339,441 股，投票權為 105,576,356 個。該信息於 2026 年 1 月 5 日通過 GlobeNewswire 發佈 | [Link](https://longbridge.com/en/news/271563455.md) | | 富國銀行重申對 Cellectis SA（CLLS）的持有評級 | Wells Fargo 分析師朱雅楠對 Cellectis SA (CLLS) 維持了持有評級，目標價為 4.00 美元。朱雅楠是一位五星級分析師，平均回報率為 14.4%，成功率為 42.07%，覆蓋醫療保健行業。對 Cellectis | [Link](https://longbridge.com/en/news/272507466.md) | | 特朗普暗示違法徵收的關税不退了，美財長稱今年關税收入將 “基本保持不變” | 美國總統特朗普暗示不會退還被最高法院裁定違法的關税，預計 2026 年關税收入將保持不變。特朗普計劃簽署行政令，對全球商品加徵 10% 進口關税，取代被推翻的關税。財長貝森特表示，政府將利用替代法律權力維持關税收入，強調國家安全和財政收入不 | [Link](https://longbridge.com/en/news/276494362.md) | | 美財政部讓步，擬修訂主權財富基金税收提案，此前遭私募業警告 | 美國財政部正就一項針對主權財富基金和公共養老基金徵税方式進行全面改革的提案作出讓步。相關提案此前由美國國税局提出，擬更新税法第 892 條，將這些基金持有的多數美國債務投資歸為商業活動，這將令其面臨被徵税的風險。此前，私募信貸和私募股權公司 | [Link](https://longbridge.com/en/news/276491732.md) | | Tempus AI 執行副總裁 Erik Phelps 出售了部分股份 | 埃裏克·菲爾普斯（Erik Phelps），Tempus AI 的執行副總裁兼首席行政官，於 2026 年 2 月 19 日出售了 9,464 股 A 類普通股，總金額為 562,472 美元。此次銷售包括 3,814 股，每股售價為 60 | [Link](https://longbridge.com/en/news/276495655.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.